HRP960616A2 - Quinoline and quinazoline compounds useful in therapy - Google Patents
Quinoline and quinazoline compounds useful in therapyInfo
- Publication number
- HRP960616A2 HRP960616A2 HR9526546.8A HRP960616A HRP960616A2 HR P960616 A2 HRP960616 A2 HR P960616A2 HR P960616 A HRP960616 A HR P960616A HR P960616 A2 HRP960616 A2 HR P960616A2
- Authority
- HR
- Croatia
- Prior art keywords
- quinoline
- therapy
- compounds useful
- quinazoline compounds
- quinazoline
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D497/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D497/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9526546.8A GB9526546D0 (en) | 1995-12-23 | 1995-12-23 | Compounds useful in therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP960616A2 true HRP960616A2 (en) | 1998-06-30 |
Family
ID=10786091
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR9526546.8A HRP960616A2 (en) | 1995-12-23 | 1996-12-23 | Quinoline and quinazoline compounds useful in therapy |
Country Status (34)
Country | Link |
---|---|
US (3) | US6103738A (de) |
EP (1) | EP0877734B1 (de) |
JP (1) | JP3070958B2 (de) |
KR (1) | KR19990076693A (de) |
AP (1) | AP715A (de) |
AR (1) | AR005166A1 (de) |
AT (1) | ATE194598T1 (de) |
AU (1) | AU708979B2 (de) |
BG (1) | BG102559A (de) |
BR (1) | BR9612263A (de) |
CA (1) | CA2236814C (de) |
CO (1) | CO4480106A1 (de) |
CZ (1) | CZ197698A3 (de) |
DE (1) | DE69609353T2 (de) |
DK (1) | DK0877734T3 (de) |
ES (1) | ES2151192T3 (de) |
GB (1) | GB9526546D0 (de) |
GR (1) | GR3034225T3 (de) |
HN (1) | HN1996000082A (de) |
HR (1) | HRP960616A2 (de) |
HU (1) | HUP9903560A3 (de) |
IS (1) | IS4731A (de) |
MA (1) | MA26414A1 (de) |
NO (1) | NO982913L (de) |
NZ (1) | NZ325248A (de) |
OA (1) | OA10703A (de) |
PL (1) | PL327610A1 (de) |
PT (1) | PT877734E (de) |
SK (1) | SK81698A3 (de) |
TN (1) | TNSN96161A1 (de) |
TR (1) | TR199801195T2 (de) |
WO (1) | WO1997023462A1 (de) |
YU (1) | YU68896A (de) |
ZA (1) | ZA9610784B (de) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9526546D0 (en) * | 1995-12-23 | 1996-02-28 | Pfizer Ltd | Compounds useful in therapy |
GB9700504D0 (en) | 1997-01-11 | 1997-02-26 | Pfizer Ltd | Pharmaceutical compounds |
GB9708917D0 (en) * | 1997-05-01 | 1997-06-25 | Pfizer Ltd | Compounds useful in therapy |
GB9711220D0 (en) * | 1997-05-30 | 1997-07-23 | Isis Innovation | Antiarrhythmic agents |
GB9711650D0 (en) * | 1997-06-05 | 1997-07-30 | Pfizer Ltd | Compounds useful in therapy |
AU9378801A (en) | 2000-08-31 | 2002-03-13 | Hoffmann La Roche | Quinazoline derivatives as alpha-1 adrenergic antagonists |
US6900220B2 (en) | 2001-01-02 | 2005-05-31 | Syntex (U.S.A.) Llc | Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists |
WO2002053558A1 (en) * | 2001-01-02 | 2002-07-11 | F.Hoffman-La Roche Ag | Quinazolone derivatives as alpha 1a/b adrenergic receptor antagonists |
US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
US6734303B2 (en) | 2001-05-18 | 2004-05-11 | Pfizer Inc. | Process for the production of quinazolines |
GB0206033D0 (en) | 2002-03-14 | 2002-04-24 | Pfizer Ltd | Compounds useful in therapy |
ES2400339T3 (es) | 2002-07-15 | 2013-04-09 | Symphony Evolution, Inc. | Compuestos, composiciones farmacéuticas de los mismos y su uso en el tratamiento del cáncer |
AU2003263455A1 (en) | 2002-09-26 | 2004-04-19 | Pfizer Inc. | Pyrazole amides for treating hiv infections |
PL1615909T3 (pl) | 2003-04-23 | 2009-01-30 | Glaxo Group Ltd | Pochodne piperazyny i ich zastosowanie w leczeniu chorób neurologicznych i psychicznych |
US20050124562A1 (en) * | 2003-09-23 | 2005-06-09 | Joseph Guiles | Bis-quinazoline compounds for the treatment of bacterial infections |
EP2609919A3 (de) | 2003-09-26 | 2014-02-26 | Exelixis, Inc. | c-Met-Modulatoren und Verwendungsverfahren |
CN101006076B (zh) * | 2004-06-24 | 2010-09-29 | 沃泰克斯药物股份有限公司 | Atp-结合弹夹转运蛋白的调控剂 |
DK3219705T3 (da) | 2005-12-28 | 2020-04-14 | Vertex Pharma | Farmaceutiske sammensætninger af den amorfe form af n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinolin-3-carboxamid |
US8986713B2 (en) * | 2006-05-12 | 2015-03-24 | W. L. Gore & Associates, Inc. | Medical device capable of being compacted and expanded having anti-thrombin III binding activity |
US8496953B2 (en) * | 2006-05-12 | 2013-07-30 | W. L. Gore & Associates, Inc. | Immobilized biologically active entities having a high degree of biological activity following sterilization |
US8021677B2 (en) | 2006-05-12 | 2011-09-20 | Gore Enterprise Holdings, Inc. | Immobilized biologically active entities having a high degree of biological activity |
US20080279909A1 (en) * | 2006-05-12 | 2008-11-13 | Cleek Robert L | Immobilized Biologically Active Entities Having A High Degree of Biological Activity Following Sterilization |
US9114194B2 (en) * | 2006-05-12 | 2015-08-25 | W. L. Gore & Associates, Inc. | Immobilized biologically active entities having high biological activity following mechanical manipulation |
CN101679308B (zh) * | 2007-03-14 | 2014-05-07 | 埃克塞里艾克西斯公司 | Hedgehog途径抑制剂 |
WO2010054968A1 (en) * | 2008-11-14 | 2010-05-20 | F. Hoffmann-La Roche Ag | Quinazoline derivatives as nk3 receptor antagonists |
TW202241853A (zh) | 2009-01-16 | 2022-11-01 | 美商艾克塞里克斯公司 | 包含n-(4-{[6,7-雙(甲氧基)喹啉-4-基]氧基}苯基)-n'-(4-氟苯基)環丙烷-1,1-二甲醯胺之蘋果酸鹽之醫藥組合物及其用途 |
PT2408750E (pt) | 2009-03-20 | 2015-10-15 | Vertex Pharma | Processo para a produção de modeladores do regulador de condutância transmembranar da fibrose cística |
JP5770158B2 (ja) * | 2009-03-23 | 2015-08-26 | シプラ・リミテッド | ドキサゾシン及びその塩の製造方法 |
UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
ES2609335T3 (es) | 2009-09-03 | 2017-04-19 | Bristol-Myers Squibb Company | Quinazolinas como inhibidores de los canales iónicos de potasio |
US8591932B2 (en) * | 2009-09-17 | 2013-11-26 | W. L. Gore & Associates, Inc. | Heparin entities and methods of use |
RU2625756C2 (ru) | 2011-03-11 | 2017-07-18 | В.Л. Гор Энд Ассошиейтс, Инк. | Усовершенствованные иммобилизованные биологические объекты |
WO2013043255A1 (en) * | 2011-09-21 | 2013-03-28 | University Of South Alabama | Methods and compositions for the treatment of ovarian cancer |
EP2819670A1 (de) | 2012-02-27 | 2015-01-07 | Vertex Pharmaceuticals Incorporated | Pharmazeutische zusammensetzung und verabreichung davon |
EP3124482B1 (de) * | 2014-03-24 | 2019-09-11 | Guangdong Zhongsheng Pharmaceutical Co., Ltd | Chinolinderivate als smo-hemmer |
RU2749213C2 (ru) | 2014-10-07 | 2021-06-07 | Вертекс Фармасьютикалз Инкорпорейтед | Сокристаллы модуляторов регулятора трансмембранной проводимости при кистозном фиброзе |
WO2018005552A1 (en) | 2016-06-27 | 2018-01-04 | Achillion Pharmaceuticals, Inc. | Quinazoline and indole compounds to treat medical disorders |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4656174A (en) * | 1982-07-24 | 1987-04-07 | Pfizer Inc. | Quinoline therapeutic agents |
GB8506174D0 (en) * | 1985-03-09 | 1985-04-11 | Pfizer Ltd | 4-amino-6 7-dimethoxy-2-piperazin-1-ylquinazoline derivatives |
GB8814458D0 (en) * | 1988-06-17 | 1988-07-20 | Wyeth John & Brother Ltd | Heterocyclic compounds |
GB9526546D0 (en) * | 1995-12-23 | 1996-02-28 | Pfizer Ltd | Compounds useful in therapy |
-
1995
- 1995-12-23 GB GBGB9526546.8A patent/GB9526546D0/en active Pending
- 1995-12-23 NZ NZ325248A patent/NZ325248A/en unknown
-
1996
- 1996-12-05 DE DE69609353T patent/DE69609353T2/de not_active Expired - Fee Related
- 1996-12-05 CA CA002236814A patent/CA2236814C/en not_active Expired - Fee Related
- 1996-12-05 BR BR9612263A patent/BR9612263A/pt not_active Application Discontinuation
- 1996-12-05 AU AU13719/97A patent/AU708979B2/en not_active Ceased
- 1996-12-05 EP EP96943954A patent/EP0877734B1/de not_active Expired - Lifetime
- 1996-12-05 JP JP9523272A patent/JP3070958B2/ja not_active Expired - Fee Related
- 1996-12-05 PL PL96327610A patent/PL327610A1/xx unknown
- 1996-12-05 DK DK96943954T patent/DK0877734T3/da active
- 1996-12-05 CZ CZ981976A patent/CZ197698A3/cs unknown
- 1996-12-05 AT AT96943954T patent/ATE194598T1/de not_active IP Right Cessation
- 1996-12-05 WO PCT/EP1996/005609 patent/WO1997023462A1/en not_active Application Discontinuation
- 1996-12-05 PT PT96943954T patent/PT877734E/pt unknown
- 1996-12-05 SK SK816-98A patent/SK81698A3/sk unknown
- 1996-12-05 TR TR1998/01195T patent/TR199801195T2/xx unknown
- 1996-12-05 HU HU9903560A patent/HUP9903560A3/hu unknown
- 1996-12-05 KR KR1019980704806A patent/KR19990076693A/ko not_active Application Discontinuation
- 1996-12-05 ES ES96943954T patent/ES2151192T3/es not_active Expired - Lifetime
- 1996-12-05 US US09/091,370 patent/US6103738A/en not_active Expired - Fee Related
- 1996-12-12 HN HN1996000082A patent/HN1996000082A/es unknown
- 1996-12-18 MA MA24433A patent/MA26414A1/fr unknown
- 1996-12-18 TN TNTNSN96161A patent/TNSN96161A1/fr unknown
- 1996-12-19 AP APAP/P/1996/000900A patent/AP715A/en active
- 1996-12-20 YU YU68896A patent/YU68896A/sh unknown
- 1996-12-20 ZA ZA9610784A patent/ZA9610784B/xx unknown
- 1996-12-20 CO CO96066994A patent/CO4480106A1/es unknown
- 1996-12-20 AR ARP960105804A patent/AR005166A1/es unknown
- 1996-12-23 HR HR9526546.8A patent/HRP960616A2/xx not_active Application Discontinuation
-
1998
- 1998-04-29 IS IS4731A patent/IS4731A/is unknown
- 1998-06-18 BG BG102559A patent/BG102559A/xx unknown
- 1998-06-22 NO NO982913A patent/NO982913L/no not_active Application Discontinuation
- 1998-06-23 OA OA9800092A patent/OA10703A/en unknown
-
2000
- 2000-08-17 GR GR20000401910T patent/GR3034225T3/el not_active IP Right Cessation
-
2001
- 2001-03-19 US US09/812,083 patent/US6642242B2/en not_active Expired - Fee Related
-
2003
- 2003-06-04 US US10/455,546 patent/US6750214B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AP9600900A0 (en) | Quinoline and quinazoline compounds useful in therapy | |
HRP980010B1 (en) | Quinoline and quinazoline compounds useful in therapy | |
GB2298422B (en) | Compounds and their use | |
ZA964334B (en) | Metallocene preparation and use | |
IL123600A0 (en) | 2(1H)-Quinolone derivatives their preparation and their use in therapy | |
EP0851759A4 (de) | Verbindungen und verfahren dazu | |
AU1886197A (en) | Quinolones and their therapeutic use | |
GB2282671B (en) | Diffusing and depixelating means | |
HU9602956D0 (en) | Porphocyanine and cnc-expanded porphyrins | |
GB9712761D0 (en) | Quinolines and their therapeutic use | |
EP0836617A4 (de) | Parevine und tachyteprine | |
ZA983740B (en) | Novel amidine derivatives and their use in therapy | |
EP0744125A3 (de) | Jodkomplex und dessen Verwendung | |
AU2512495A (en) | Therapeutic phenoxyalkylazoles and phenoxyalkylazines | |
EP0799225A4 (de) | Verbindungen und verfahren | |
GB9523066D0 (en) | Compounds and their therapeutic use | |
ZA959512B (en) | Aryloxycycloalkenyl and aryloxyiminocycloalkenylhy-droxyureas | |
ZA9710000B (en) | Quinolines and their therapeutic use | |
GB9714298D0 (en) | Quinolines and their therapeutic use | |
GB9611898D0 (en) | Quinolones and their therapeutic use | |
PH30681A (en) | Imidazotriazolo quinazoline compounds and their use | |
GB9702929D0 (en) | Quinolones and their therapeutic use | |
GB9702933D0 (en) | Quinolones and their therapeutic use | |
IL128220A0 (en) | Quinoline derivatives and uses thereof | |
GB9621314D0 (en) | Substances and their therapeutic use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AIPI | Request for the grant of a patent on the basis of a substantive examination of a patent application | ||
A1OB | Publication of a patent application | ||
ODRP | Renewal fee for the maintenance of a patent |
Payment date: 19991223 Year of fee payment: 4 |
|
ODBC | Application rejected |